The effect of?ulinastatin on vascular endothelial cells and blood coagulation in pregnant women with severe pre-eclampsia

Ulinastatin attenuates vascular endothelial cell damage in pregnant women with severe pre-eclampsia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800014898

Enrollment

Unknown

Registered

2018-02-13

Start date

2016-02-09

Completion date

Unknown

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pregnant women with severe pre-eclampsia

Interventions

Case series:ulinastatin

Eligibility

Sex/Gender

Female

Age

22 Years to 39 Years

Inclusion criteria

Inclusion criteria: Pregnant women with severe PE who elected to undergo cesarean section were enrolled in our study.

Exclusion criteria

Exclusion criteria: Placenta previa, placental abruption, twins or multiple gestations, fetal structural/genetic anomaly, maternal renal disease, inflammatory disease, cancer, metabolic disease, autoimmune disease, and other comorbidities associated with endothelial damage.

Design outcomes

Primary

Measure	Time frame
vascular endothelial cell;	—

Secondary

Measure	Time frame
vWF, platelet granule membrane protein (GMP-140), platelet count, prothrombin time (PT), partial prothrombin activation time (APTT), and fibrinogen levels;	—

Contacts

Public ContactJianbo Wang

Tianjin Central Hospital of Gynecology and Obstetrics

wjb6322@163.com+86 18920196061

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026